Expression of Erythroid Differentiation Regulator 1 (Erdr1) in Vitiligo

Expression of Erythroid Differentiation Regulator 1 (Erdr1) Cytokine in the Vitiliginous Skin Lesions: a Case Control Study

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03377998

Enrollment

100

Registered

2017-12-19

Start date

2018-01-31

Completion date

2018-07-31

Last updated

2017-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erythroid Differentiation Regulator 1 (Erdr1) Cytokine

Brief summary

Expression of Erythroid differentiation regulator 1 (Erdr1) cytokine in vitiligo

Interventions

OTHERskin biopsy

Skin biopsy for measuring tissue levels of the Erythroid differentiation regulator 1 (Erdr1) cytokine will be taken from the lesional skin of patients of vitiligo and from normal skin of healthy controls.

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Patients with generalized non-segmental vitiligo. * Both sexes. * Age \>18 years old. * New cases or cases not receiving any medication for at least 3 months ago.

Exclusion criteria

* Segmental or Universal vitiligo * Autoimmune diseases

Design outcomes

Primary

Measure	Time frame	Description
Expression of tissue levels of erythroid differentiation regulator 1 (Erdr1) cytokine in patients of vitiligo	6 months	Expression of tissue levels of erythroid differentiation regulator 1 (Erdr1) cytokine in patients of vitiligo and comparing its level in normal subjects

Contacts

Primary ContactMaha Fathy Elmasry, MD

mahafathy1214@gmail.com00201222633740

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026